

## QIBA SPECT Biomarker Committee (BC)

Friday, June 16, 2017, 9 AM (CT)

Call Summary

### In attendance:

*Yuni Dewaraja, PhD (Co-Chair)*

*P. David Mozley, MD (Co-Chair)*

*John Seibyl, MD (Co-Chair)*

John Dickson, PhD

Eric Frey, PhD

Paul Kinahan, PhD

Robert Miyaoka, PhD

Eric Perlman, MD

Anne Smith, PhD

Richard Wahl, MD, FACR

Brian Zimmerman, PhD

### RSNA

Joe Koudelik

Julie Lisiecki

**Moderator:** Dr. Mozley

### Call Scheduling

- The next SPECT BC meeting is scheduled for July 21<sup>st</sup>
- If needed, an ad hoc I-123 Profile Task Force (TF) call may be scheduled for Tuesday, June 27<sup>th</sup> at 2 pm CT, if any additional high priority public comment responses are received from QIBA Japan or other reviewers.
- As TF calls resume, they will be scheduled as follows:
  - The first Tuesday of the month will be for I-123 (Drs. Seibyl and Dickson)
  - The second Tuesday of the month will be for the Technetium Profile (Tc <sup>99m</sup>) (Drs. Dewaraja and Mozley)
  - Current participants interested in participating on one or both of these committees are asked to make their preference known by responding to RSNA Staff ([jlisiecki@rsna.org](mailto:jlisiecki@rsna.org)) or Dr. Mozley ([mozley@gmail.com](mailto:mozley@gmail.com))
  - Technical scribes may be needed for these calls. If interested, please respond to Dr. Mozley ([mozley@gmail.com](mailto:mozley@gmail.com))

### I-123 Ioflupane Profile: Next Steps

- A formal memo response was sent to QIBA Japan and other reviewers on June 6<sup>th</sup>: The group is awaiting any additional response
  - Absolute quantification was highly encouraged; however it is simply not possible to make this the minimally acceptable standard in multisite trials or ordinary clinical practice at the present time
  - Current groundwork projects may provide additional clarification of claims
    - Either claims will be shown to be not feasible or claims will be documented with “known issues”
- A cross section claim regarding system calibration may not be possible since bias is not known
- A discriminatory claim was re-purposed as a “Statement of Clinical Use” or a “Potential Clinical Use Case” which references clinical utility, thereby making the Profile more valuable in clinical practice
- In the meantime, cleanup of comments continues, to move the Profile to the next phase: Technical Conformance
- A clean version of the Profile will be used to create a checklist, and will be posted to the wiki on June 30<sup>th</sup>
- A NM CC vote will be needed prior to June 30<sup>th</sup> to approve this move to the Technical Conformance phase on July 1<sup>st</sup>
- Some additional review of passages within the Profile to continue on Dropbox by the team

### New members

- All are asked to recruit new members regularly; new names can be sent to [qiba@rsna.org](mailto:qiba@rsna.org)
- Volunteers willing to moderate BC or TF calls would be appreciated
  - Please email the SPECT BC co-chairs if interested: [yuni@umich.edu](mailto:yuni@umich.edu); [mozley@gmail.com](mailto:mozley@gmail.com); [jseibyl@mrimaging.com](mailto:jseibyl@mrimaging.com)
- Previous meeting agendas, Profile versions, and work products are available in the group’s [Dropbox folder](#)
- Opportunities to meet and recruit new members may present themselves at the following meetings:
  - October, Vienna: EANM annual meeting
  - December, Chicago: RSNA annual meeting

